BS PHARM KOREA successfully concluded its participation in IMCAS China 2026, held from August 27–29 at W Shanghai – The Bund.
As a Silver Sponsor, BS PHARM KOREA participated at Booth 65 and presented its professional aesthetic portfolio to visitors throughout the three-day congress. The official IMCAS China 2026 program listed BS PHARM KOREA among the Silver Sponsors and exhibitors.
During the exhibition, INHILO+ and NA:DRN received particularly strong interest at our booth. Discussions focused on formulation concepts, product differentiation, and potential distribution opportunities.
IMCAS China 2026 brought together the international medical aesthetics community for three days of scientific education, clinical discussion, and industry exchange.
According to the official post-congress report, the fifth edition welcomed 2,423 participants from 86 countries. It also featured 292 speakers, 84 sessions, and 75 exhibitors.
The scientific program covered 15 themes across eight rooms. In total, IMCAS China 2026 delivered 113 learning hours and 685 presentations, supported by five scientific partners.
These figures highlight both the international reach and scientific scale of the congress.
A Truly International Medical Aesthetics Congress
The official participation data shows the broad international reach of IMCAS China 2026.
While China represented the largest participant group with 804 attendees, the congress also welcomed significant participation from other markets. Russia recorded 439 attendees, followed by Vietnam with 124, South Korea with 121, and Kazakhstan with 107.
Other leading represented countries included Indonesia, France, Malaysia, Bangladesh, and Spain. Overall, professionals from 86 countries attended the congress.
This international participation reinforced IMCAS China’s role as a platform for scientific exchange and professional networking across the global aesthetics community.
Injectables Among Key Congress Topics
injectables were prominent topics during IMCAS China 2026.
In the official delegate evaluation, Injectables ranked as the second favorite session, while Injectables and Combined Approach – Periorbital ranked third. Another injectable-focused session on botulinum toxin also appeared among the top ten.
The Injectables program covered topics such as structural refinement, anatomy-based facial contouring, and combination approaches. This reflected continued scientific interest in more precise and differentiated injectable strategies.
The scientific program also covered broader themes such as Face Surgery, Lasers, EBD & Body Shaping, Clinical Dermatology & Dermatologic Surgery, and Regenerative Medicine.
Strong Interest in INHILO+ and NA:DRN
At the BS PHARM KOREA booth, INHILO+ and NA:DRN were among the products that received the strongest interest from visitors.
The conversations reflected different areas of interest for each product. INHILO+ generated questions around its HA formulation and cross-linking concept. Meanwhile, discussions around NA:DRN focused mainly on its formulation.
These conversations also reflected broader topics highlighted throughout the congress, particularly injectables and regenerative medicine.
INHILO+: Focus on Dual HA and Cross-Linking
INHILO+ attracted strong interest for its Dual HA formulation and cross-linking approach.
Visitors frequently asked about the combination of high- and low-molecular-weight hyaluronic acid. In particular, the cross-linking concept led to discussions about how the formulation differs from other HA-based approaches.
Distribution opportunities were another recurring topic during conversations around INHILO+.
This interest was especially relevant within the wider context of IMCAS China 2026, where injectables represented the largest scientific program theme by learning hours.
Overall, the response showed clear interest in differentiated HA formulation concepts within the professional aesthetic market.
NA:DRN: Interest in NAD+ and PDRN Formulation
NA:DRN also received strong interest during the exhibition.
Many discussions focused on its formulation combining NAD+ and PDRN. Visitors were particularly interested in the concept behind the combination and how the formulation differs from more conventional ingredient approaches.
This interest also aligned with the broader scientific direction of IMCAS China 2026, where Regenerative Medicine was included among the major program themes.
These discussions reflected wider interest in ingredient-driven and regenerative aesthetic concepts.
What We Learned at IMCAS China 2026
Several themes stood out during the congress.
First, injectables remained a major focus at IMCAS China 2026. Injectables represented the largest scientific program theme by learning hours. In addition, injectable-focused sessions ranked second and third among delegates’ favorite sessions.
Second, regenerative concepts continued to attract attention. Regenerative Medicine was included among the major scientific program themes.
In addition, our booth discussions showed strong interest in formulation differentiation. Visitors wanted to understand not only which ingredients were included, but also how different formulation concepts could be positioned in their markets.
Finally, distributor discussions went beyond product specifications. Market suitability, positioning, and potential long-term collaboration were also common topics.
Looking Ahead After IMCAS China 2026
BS PHARM KOREA would like to thank everyone who visited Booth 65 during IMCAS China 2026.
The congress provided an important opportunity to present our aesthetic portfolio and discuss new formulation concepts with professionals attending the event.
In particular, the response to INHILO+ and NA:DRN provided useful feedback on current interest in differentiated skin booster and regenerative aesthetic formulations.
Following IMCAS China 2026, BS PHARM KOREA will continue to strengthen its global presence and expand opportunities for international collaboration.
We look forward to meeting more partners at our upcoming international exhibitions, including Dubai Derma 2026, and continuing discussions around skin quality, regenerative aesthetics, and professional aesthetic solutions.
Learn More About BS PHARM KOREA
Explore our range of skin boosters, dermal fillers, ingredient-focused aesthetic solutions, and professional beauty products.
For product information, distribution inquiries, or partnership opportunities, please contact the BS PHARM KOREA team.
